Hemostemix continues to flourish in the healthcare sector.
Hemostemix Inc. (TSXV: HEM) has emerged as a pioneer biotechnology company in the healthcare sector. This company is continuously thriving to shape and develop blood-derived stem cell therapies for medical conditions. With its innovative approach and proficient technology, the company constantly tries to improve the lives of patients with cardiovascular diseases, autoimmune diseases, and other medical conditions. Hemostemix Inc. tries to revolutionize the field of regenerative medicine by offering hope to millions of people around the world. This company has effective proprietary platform technology. This proprietary platform technology is based on 10 years of clinical data, which demonstrates the ability of our autologous cell product for regeneration of damaged and diseased tissue.
Recently, the company Hemostemix Inc. announced that it was re-pricing its 14 million common share units to $0.20 each. Basically, each unit consists of one common share in the capital of the company (referred to as the "common share") and one common share purchase warrant (referred to as the "warrant"). Subject to the accelerated expiry provision detailed below, each full warrant entitles the holder to purchase one common share for $0.65 per common share for a period of 24 months following the closing of the offering.
According to the prospectus exemption underlined in Alberta Securities Commission Rule 45-513, "Prospectus Exemption for Distribution to Existing Security Holders," and in comparable documents in other Canadian provinces and territories, the offering is made available mostly to current shareholders of the company who, as of the close of business on January 2, 2023, hold common shares of the company. The existing shareholder exemption restricts a shareholder to a maximum investment of $15,000 over the course of a year unless the shareholder has sought advice about the investment's suitability, and, if the shareholder resides in a Canadian jurisdiction, that advice has been sought from a person who is registered as an investment dealer in that jurisdiction. The company intends to prorate the subscriptions received in the event that subscriptions received from investors who depend on the current shareholder exemption exceed the financing's maximum amount. Additionally, the company made the offering available to a select group of subscribers in accordance with the investment dealer exemption. The company verifies that there are no relevant facts or major changes regarding the company that have not been generally reported in compliance with the requirements of the investment dealer exemption.
Recently, the company Hemostemix Inc. announced that it was re-pricing its 14 million common share units to $0.20 each. Basically, each unit consists of one common share in the capital of the company (referred to as the "common share") and one common share purchase warrant (referred to as the "warrant"). Subject to the accelerated expiry provision detailed below, each full warrant entitles the holder to purchase one common share for $0.65 per common share for a period of 24 months following the closing of the offering.
According to the prospectus exemption underlined in Alberta Securities Commission Rule 45-513, "Prospectus Exemption for Distribution to Existing Security Holders," and in comparable documents in other Canadian provinces and territories, the offering is made available mostly to current shareholders of the company who, as of the close of business on January 2, 2023, hold common shares of the company. The existing shareholder exemption restricts a shareholder to a maximum investment of $15,000 over the course of a year unless the shareholder has sought advice about the investment's suitability, and, if the shareholder resides in a Canadian jurisdiction, that advice has been sought from a person who is registered as an investment dealer in that jurisdiction. The company intends to prorate the subscriptions received in the event that subscriptions received from investors who depend on the current shareholder exemption exceed the financing's maximum amount. Additionally, the company made the offering available to a select group of subscribers in accordance with the investment dealer exemption. The company verifies that there are no relevant facts or major changes regarding the company that have not been generally reported in compliance with the requirements of the investment dealer exemption.
Clause de non-responsabilité
Les informations et les publications ne sont pas destinées à être, et ne constituent pas, des conseils ou des recommandations en matière de finance, d'investissement, de trading ou d'autres types de conseils fournis ou approuvés par TradingView. Pour en savoir plus, consultez les Conditions d'utilisation.